The Two Faces of Galectin-3: Roles in Various Pathological Conditions

Gordana D. Radosavljevic; Jelena Pantic; Ivan Jovanovic; Miodrag L. Lukic; Nebojsa Arsenijevic

doi:10.1515/sjecr-2016-0011

.blurhash-client-img { display: none !important; }

The Two Faces of Galectin-3: Roles in Various Pathological Conditions

EABR. Experimental and Applied Biomedical Research

Volume 17 (2016): Issue 3 (September 2016)

By: Gordana D. Radosavljevic, Jelena Pantic, Ivan Jovanovic, Miodrag L. Lukic and Nebojsa Arsenijevic

Open Access

|Sep 2016

Abstract

Galectin-3, a unique chimaera-type member of the lectin family, displays a wide range of activities. This versatile molecule is involved in fundamental biological processes, including cell proliferation, cell-cell adhesion, apoptosis and immune responses.

This review is aimed at providing a general overview of the biological actions and diverse effects of Galectin-3 in many pathological conditions, with a specific focus on autoimmunity, inflammation and tumour progression. We report herein that Galectin-3 exerts deleterious functions determined by promotion of tumour progression and liver inflammation or aggravation of T cell-mediated autoimmune diseases. On the other hand, Galectin-3 exhibits a protective role in metabolic abnormalities and primary biliary cirrhosis.

The paradoxical “yin and yang” functions of Galectin-3 depend not only on its tissue and cellular localization but also on its availability, glycosylation status and the expression level of its ligands.

References

1. Liu FT, Rabinovich GA. (2005). Galectins as modulators of tumour progression. Nat Rev Cancer, 5(1), 29-41.10.1038/nrc1527
Search in Google Scholar Back to article
2. Radosavljevic G, Volarevic V, Jovanovic I, Milovanovic M, Pejnovic N, Arsenijevic N, et al. (2012). The roles of Galectin-3 in autoimmunity and tumor progression. Immunol Res, 52,100–110.10.1007/s12026-012-8286-6
Search in Google Scholar Back to article
3. Moutsatsos IK, Wade M, Schindler M, Wang JL. (1987). Endogenous lectins from cultured cells: nuclear localization of carbohydrate binding protein 35 in proliferating 3T3 fibroblasts. Proc Natl Acad Sci USA, 84, 6452–6456.10.1073/pnas.84.18.6452
Search in Google Scholar Back to article
4. Yu F, Finley R, Raz A, Kim H-RC. (2002). Galectin-3 translocates to the perinuclear membranes and inhibits cytochrome c release from the mitochondria. A role for synexin in galectin-3 translocation. J Biol Chem, 277(18), 15819–15827.10.1074/jbc.M200154200
Search in Google Scholar Back to article
5. Paron I, Scaloni A, Pines A, Bachi A, Liu F-T, Puppin C, et al. (2003). Nuclear localization of Galectin-3 in transformed thyroid cells:a role in transcriptional regulation. Biochem Biophys Res Commun, 302(3), 545–553.10.1016/S0006-291X(03)00151-7
Search in Google Scholar Back to article
6. Dagher SF, Wang JL, Patterson RJ. (1995). Identification of galectin-3 as a factor in pre-mRNA splicing. Proc Natl Acad Sci USA, 92(4), 1213–1217.10.1073/pnas.92.4.1213426697862663
Search in Google Scholar Back to article
7. Wang JL, Gray RM, Haudek KC, Patterson RJ. (2004). Nucleocytoplasmic lectins. Biochim Biophys Acta, 1673(1–2), 75–93.10.1016/j.bbagen.2004.03.01315238251
Search in Google Scholar Back to article
8. Yang RY, Hsu DK, Liu FT. (1996). Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci USA, 93, 6737–6742.10.1073/pnas.93.13.6737390968692888
Search in Google Scholar Back to article
9. Califice S, Castronovo V, Bracke M, van den Brûle F. (2004). Dual activities of galectin-3 in human prostate cancer: tumor suppression of nuclear galectin-3 vs tumor promotion of cytoplasmic galectin-3. Oncogene, 23(45), 7527–7536.10.1038/sj.onc.120799715326483
Search in Google Scholar Back to article
10. Nakahara S, Oka N, Raz A. (2005). On the role of galectin-3 in cancer apoptosis. Apoptosis, 10(2), 267–275.10.1007/s10495-005-0801-y15843888
Search in Google Scholar Back to article
11. Scaffidi C, Fulda S, Srinivasan A, Friesen C, Li F, Tomaselli KJ, et al. (1998). Two CD95 (APO-1/Fas) signaling pathways. EMBO J, 17(6), 1675-1687.10.1093/emboj/17.6.167511705159501089
Search in Google Scholar Back to article
12. Fukumori T, Takenaka Y, Oka N, Yoshii T, Hogan V, Inohara H, et al. (2004). Endogenous galectin-3 determines the routing of CD95 apoptotic signaling pathways. Cancer Res, 64(10), 3376-3379.10.1158/0008-5472.CAN-04-033615150087
Search in Google Scholar Back to article
13. Hsu DK, Chen HY, Liu FT. (2009). Galectin-3 regulates T-cell functions. Immunol Rev, 230(1), 114-127.10.1111/j.1600-065X.2009.00798.x19594632
Search in Google Scholar Back to article
14. Dumic J, Dabelic S, Flögel M. (2006). Galectin-3: an open-ended story. Biochim Biophys Acta, 1760, 616–635.10.1016/j.bbagen.2005.12.02016478649
Search in Google Scholar Back to article
15. Funasaka T, Raz A, Nangia-Makker P. (2014). Galectin-3 in angiogenesis and metastasis. Glycobiology, 24(10), 886–891.10.1093/glycob/cwu086415376025138305
Search in Google Scholar Back to article
16. Yu L-G. (2010). Circulating galectin-3 in the blood-stream: An emerging promoter of cancer metastasis. World J Gastrointest Oncol, 2(4), 177-180.10.4251/wjgo.v2.i4.177299918221160594
Search in Google Scholar Back to article
17. Braeuer RR, Shoshan E, Kamiya T, Bar-Eli M. (2012). The sweet and bitter sides of galectins in melanoma progression. Pigment Cell Melanoma Res, 25(5), 592-601.10.1111/j.1755-148X.2012.01026.x22672152
Search in Google Scholar Back to article
18. Sano H, Hsu DK, Yu L, Apgar JR, Kuwabara I, Yamanaka T, et al. (2000). Human galectin-3 is a novel chemoattractant for monocytes and macrophages. J Immunol, 165, 2156–2164.10.4049/jimmunol.165.4.215610925302
Search in Google Scholar Back to article
19. Ochieng J, Leite-Browning ML, Warfield P. (1998). Regulation of cellular adhesion to extracellular matrix proteins by galectin-3. Biochem Biophys Res Commun, 246, 788–791.10.1006/bbrc.1998.87089618290
Search in Google Scholar Back to article
20. Demetriou M, Granovsky M, Quaggin S, Dennis JW. (2001). Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature, 409, 733–739.10.1038/3505558211217864
Search in Google Scholar Back to article
21. Breuilh L, Vanhoutte F, Fontaine J, van Stijn CM, Tillie-Leblond I, Capron M, et al. (2007). Galectin-3 modulates immune and inflammatory responses during helminthic infection: impact of galectin-3 deficiency on the functions of dendritic cells. Infect Immun, 75, 5148–5157.10.1128/IAI.02006-06216830417785480
Search in Google Scholar Back to article
22. Wu SY, Yu JS, Liu FT, Miaw SC, Wu-Hsieh BA. (2013). Galectin-3 negatively regulates dendritic cell production of IL-23/IL-17-axis cytokines in infection by Histoplasma capsulatum. J Immunol, 190, 3427–3437.10.4049/jimmunol.120212223455499
Search in Google Scholar Back to article
23. Cortegano I, del Pozo V, Cárdaba B, de Andrés B, Gallardo S, del Amo A et al. (1998). Galectin-3 down-regulates IL-5 gene expression on different cell types. J Immunol, 161, 385–389.10.4049/jimmunol.161.1.385
Search in Google Scholar Back to article
24. Ruas LP, Bernardes ES, Fermino ML, de Oliveira LL, Hsu DK, Liu FT. et al. (2009). Lack of galectin-3 drives response to Paracoccidioides brasiliensis toward a Th2-biased immunity. PLoS One, 4, e4519.10.1371/journal.pone.0004519264100319229338
Search in Google Scholar Back to article
25. Bernardes ES, Silva NM, Ruas LP, Mineo JR, Loyola AM, Hsu DK, et al. (2006). Toxoplasma gondii infection reveals a novel regulatory role for galectin-3 in the interface of innate and adaptive immunity. Am J Pathol, 168, 1910–1920.10.2353/ajpath.2006.050636160662816723706
Search in Google Scholar Back to article
26. Ochieng J, Furtak V, Lukyanov P. (2004). Extracellular functions of galectin-3. Glycoconj J, 19, 527–535.10.1023/B:GLYC.0000014082.99675.2f
Search in Google Scholar Back to article
27. Mishra BB, Li Q, Steichen AL, Binstock BJ, Metzger DW, Teale JM, et al. (2013). Galectin-3 functions as an alarmin: pathogenic role for sepsis development in murine respiratory tularemia. PLoS One, 8(3), e59616.10.1371/journal.pone.0059616360390823527230
Search in Google Scholar Back to article
28. Iacobini C, Menini S, Oddi G, Ricci C, Amadio L, Pricci F, et al. (2004). Galectin-3/AGE-receptor 3 knockout mice show accelerated AGE-induced glomerular injury: evidence for a protective role of galectin-3 as an AGE receptor. FASEB Journal, 18, 1773–1775.10.1096/fj.04-2031fje15361471
Search in Google Scholar Back to article
29. Pejnovic NN, Pantic JM, Jovanovic IP, Radosavljevic GD, Djukic ALj, Arsenijevic NN, et al. (2013). Galectin-3 is a regulator of metaflammation in adipose tissue and pancreatic islets. Adipocyte, 2(4), 266-271.10.4161/adip.24881377470424052904
Search in Google Scholar Back to article
30. Vlassara H, Li YM, Imani F, Wojciechowicz D, Yang Z, Liu FT et al. (1995). Identification of galectin-3 as a high-affinity binding protein for advanced glycation end products (AGE): a new member of the AGE-receptor complex. Mol Med, 1, 634–646.10.1007/BF03401604
Search in Google Scholar Back to article
31. Karlsen AE, Størling ZM, Sparre T, Larsen MR, Mahmood A, Størling J, et al. (2006). Immune-mediated beta-cell destruction in vitro and in vivo-A pivotal role for galectin-3. Biochem Biophys Res Commun, 344, 406-415.10.1016/j.bbrc.2006.03.10516600178
Search in Google Scholar Back to article
32. Pejnovic NN, Pantic JM, Jovanovic IP, Radosavljevic GD, Milovanovic MZ, Nikolic IG, et al. (2013). Galectin-3 deficiency accelerates high-fat diet-induced obesity and amplifies inflammation in adipose tissue and pancreatic islets. Diabetes, 62(6), 1932-1944.10.2337/db12-0222366161123349493
Search in Google Scholar Back to article
33. MacKinnon AC, Farnworth SL, Hodkinson PS, Henderson NC, Atkinson KM, Leffler H, et al. (2008). Regulation of alternative macrophage activation by galectin-3. J Immunol, 180, 2650–2658.10.4049/jimmunol.180.4.265018250477
Search in Google Scholar Back to article
34. Zhou R, Tardivel A, Thorens B, Choi I, Tschopp J. (2010). Thioredoxin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol, 11, 136–140.10.1038/ni.183120023662
Search in Google Scholar Back to article
35. Vandanmagsar B, Youm YH, Ravussin A, Galgani JE, Stadler K, Mynatt RL, et al. (2011). The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med, 17,179-188.10.1038/nm.2279307602521217695
Search in Google Scholar Back to article
36. Angulo P. (2007). Obesity and nonalcoholic fatty liver disease. Nutr Rev, 65, S57–S63.10.1301/nr.2007.jun.S57-S63
Search in Google Scholar Back to article
37. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. (2012). The diagnosis and management of non-alcoholic fatty liver disease: Practice guideline by the american associations for the study of liver diseases, American college of gastroenterology, and the American gastroenterologycal association. Hepatology, 55(6), 2005-2023.10.1002/hep.2576222488764
Search in Google Scholar Back to article
38. Pugliese G, Iacobini C, Pesce CM, Menini S. (2015). Galectin-3: an emerging all-out player in metabolic disorders and their complications. Glycobiology, 25(2), 136-150.10.1093/glycob/cwu11125303959
Search in Google Scholar Back to article
39. Rhodes DH, Pini M, Castellanos KJ, Montero-Melendez T, Cooper D, Perretti M, et al. (2013). Adipose tissue specific modulation of galectin expression in lean and obese mice: Evidence for regulatory function. Obesity (Silver Spring), 21, 310-319.10.1002/oby.20016361079323401338
Search in Google Scholar Back to article
40. Butscheid M, Hauptvogel P, Fritz P, Klotz U, Alscher D. (2007). Hepatic expression of Galectin-3 and RAGE in patients with liver disease. J Clin Pathol, 60, 415–418.10.1136/jcp.2005.032391200111716775125
Search in Google Scholar Back to article
41. Jeftic I, Jovicic N, Pantic J, Arsenijevic N, Lukic ML, Pejnovic N. (2015). Galectin-3 Ablation Enhances Liver Steatosis, but Attenuates Inflammation and IL-33-Dependent Fibrosis in Obesogenic Mouse Model of Nonalcoholic Steatohepatitis. Mol Med, 21, 453-465.10.2119/molmed.2014.00178455952826018806
Search in Google Scholar Back to article
42. Volarevic V, Milovanovic M, Ljujic B, Pejnovic N, Arsenijevic N, Nilsson U, et al. (2012). Galectin-3 deficiency prevents concanavalin A-induced hepatitis in mice. Hepatology, 55(6), 1954-1964.10.1002/hep.2554222213244
Search in Google Scholar Back to article
43. Tiegs G, Hentschel J, Wendel A. (1992). A T cell-dependent experimental liver injury in mice inducible by concanavalin A. J Clin Invest, 90(1), 196–203.10.1172/JCI1158364430811634608
Search in Google Scholar Back to article
44. Kaplan MM, Gershwin ME. (2005). Primary biliary cirrhosis. The New England Journal of Medicine, 353(12), 1261–1273.10.1056/NEJMra04389816177252
Search in Google Scholar Back to article
45. Gershwin ME, Mackay IR. (2008). The causes of primary biliary cirrhosis: Convenient and inconvenient truths. Hepatology, 47(2), 737-745.
Search in Google Scholar Back to article
46. Chuang YH, Lan RY, Gershwin ME. (2009). The immunopathology of human biliary cell epithelium. Semin Immunopathol, 31,323-331.10.1007/s00281-009-0172-519533127
Search in Google Scholar Back to article
47. Kimura Y, Leung PS, Kenny TP, Van De Water J, Nishioka M, Giraud AS, et al. (2002). Differential expression of intestinal trefoil factor in biliary epithelial cells of primary biliary cirrhosis. Hepatology, 36(5), 1227-1235.10.1053/jhep.2002.3615712395334
Search in Google Scholar Back to article
48. Sasaki M, Nakanuma Y. (2010). Biliary Epithelial Apoptosis, Autophagy, and Senescence in Primary Biliary Cirrhosis. Hepatitis Research and Treatment, 2010, 205128.10.1155/2010/205128298986221152179
Search in Google Scholar Back to article
49. Mensah-Brown EP, Al Rabesi Z, Shahin A, Al Shamsi M, Arsenijevic N, Hsu DK, et al. (2009). Targeted disruption of the galectin-3 gene results in decreased susceptibility to multiple low dose streptozotocin-induced diabetes in mice. Clin Immunol, 130, 83-88.10.1016/j.clim.2008.08.02418845486
Search in Google Scholar Back to article
50. Jiang HR, Al Rasebi Z, Mensah-Brown E, Shahin A, Xu D, Goodyear CS, et al. (2009). Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis. J Immunol, 182, 1167-1173.10.4049/jimmunol.182.2.116719124760
Search in Google Scholar Back to article
51. Takenaka Y, Fukumori T, Raz A. (2004). Galectin-3 and metastasis. Glycoconj J, 19, 543-549.10.1023/B:GLYC.0000014084.01324.15
Search in Google Scholar Back to article
52. Miyazaki J, Hokari R, Kato S, Tsuzuki Y, Kawaguchi A, Nagao S, et al. (2002). Increased expression of galectin-3 in primary gastric cancer and the metastatic lymph nodes. Oncol Rep, 9(6), 1307-1312.10.3892/or.9.6.1307
Search in Google Scholar Back to article
53. Jiang S-S, Weng D-S, Wang Q-J, Pan Ke, Zhang Y-J, Li Y-Q, et al. (2014). Galectin-3 is associated with a poor prognosis in primary hepatocellular carcinoma. J Transl Med, 12, 273.
Search in Google Scholar Back to article
54. Thijssen VL, Heusschen R, Caers J, Griffioen AW. (2015). Galectin expression in cancer diagnosis and prognosis: a systematic review. Biochim Biophys Acta, 1855, 235–247.10.1016/j.bbcan.2015.03.003
Search in Google Scholar Back to article
55. Chiu CG, Strugnell SS, Griffith OL, Jones SJ, Gown AM, Walker B, et al. (2010). Diagnostic utility of galectin-3 in thyroid cancer. Am J Pathol, 176, 2067-2081.10.2353/ajpath.2010.090353
Search in Google Scholar Back to article
56. Cheng CL, Hou HA, Lee MC, Liu CY, Jhuang JY, Lai YJ, et al. (2013). Higher bone marrow LGALS3 expression is an independent unfavorable prognostic factor for overall survival in patients with acute myeloid leukemia. Blood, 121, 3172–3180.10.1182/blood-2012-07-443762
Search in Google Scholar Back to article
57. Prieto VG, Mourad-Zeidan AA, Melnikova V, Johnson MM, Lopez A, Diwan AH, et al. (2006). Galectin-3 expression is associated with tumor progression and pattern of sun exposure in melanoma. Clin Cancer Res, 12(22), 6709-6715.10.1158/1078-0432.CCR-06-0758
Search in Google Scholar Back to article
58. de Oliveira JT, Ribeiro C, Barros R, Gomes C, de Matos AJ, Reis CA, et al. (2015). Hypoxia Up-Regulates Galectin-3 in Mammary Tumor Progression and Metastasis. PLoS One, 10(7), e0134458.10.1371/journal.pone.0134458
Search in Google Scholar Back to article
59. Iurisci I, Tinari N, Natoli C, Angelucci D, Cianchetti E, Iacobelli S. (2000). Concentrations of galectin-3 in the sera of normal controls and cancer patients. Clin Cancer Res, 6, 1389-1393.
Search in Google Scholar Back to article
60. Saussez S, Lorfevre F, Lequeux T, Laurent G, Chantrain G, Vertongen F, et al. (2008). The determination of the levels of circulating galectin-1 and -3 in HNSCC patients could be used to monitor tumor progression and/or responses to therapy. Oral Oncol, 44, 86-93.10.1016/j.oraloncology.2006.12.014
Search in Google Scholar Back to article
61. Vereecken P, Zouaoui Boudjeltia K, Debray C, Awada A, Legssyer I, Sales F, et al. (2006). High serum galectin-3 in advanced melanoma: preliminary results. Clin Exp Dermatol, 31, 105-109.10.1111/j.1365-2230.2005.01992.x
Search in Google Scholar Back to article
62. Takenaka Y, Inohara H, Yoshii T, Oshima K, Nakahara S, Akahani S, et al. (2003). Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett, 195(1),111–119.10.1016/S0304-3835(03)00056-9
Search in Google Scholar Back to article
63. Elad-Sfadia G, Haklai R, Balan E, Kloog Y. (2004). Galectin-3 augments K-Ras activation and triggers a Ras signal that attenuates ERK but not phosphoinositide 3-kinase activity. J Biol Chem, 279(33), 34922–34930.10.1074/jbc.M31269720015205467
Search in Google Scholar Back to article
64. Nakayama R, Kuroda J, Taniyama N, Yamamoto-Sugitani M, Wada S, Kiyota M, et al. (2014). Suppression of SERPINA1-albumin complex formation by galectin-3 overexpression leads to paracrine growth promotion of chronic myelogenous leukemia cells. Leuk Res, 38(1), 103–108.10.1016/j.leukres.2013.07.02623953881
Search in Google Scholar Back to article
65. Khaldoyanidi S, Glinsky V, Sikora L, Glinskii A, Mossine V, Quinn T, et al. (2003). MDA-MB-435 human breast carcinoma cell homo-and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions. J Biol Chem, 278(6), 4127–4134.10.1074/jbc.M209590200
Search in Google Scholar Back to article
66. Boscher C, Zheng Y, Lakshminarayan R, Johannes L, Dennis J, Foster L, et al. (2012). Galectin-3 protein regulates mobility of N-cadherin and GM1 ganglioside at cell-cell junctions of mammary carcinoma cells. J Biol Chem, 287(39), 32940–32952.10.1074/jbc.M112.353334
Search in Google Scholar Back to article
67. Boscher C, Nabi I. (2013). Galectin-3-and phospho-caveolin-1-dependent outside-in integrin signaling mediates the EGF motogenic response in mammary cancer cells. Mol Biol Cell, 24(13), 2134–2145.10.1091/mbc.e13-02-0095
Search in Google Scholar Back to article
68. Zhang D, Chen Z-G, Liu S-H, Dong Z-Q, Dalin M, Bao S-S, et al. (2013). Galectin-3 gene silencing inhibits migration and invasion of human tongue cancer cells in vitro via downregulating b-catenin. Acta Pharmacol Sin, 34(1), 176–184.10.1038/aps.2012.150
Search in Google Scholar Back to article
69. Tsuboi K, Shimura T, Masuda N, Ide M, Tsutsumi S, Yamaguchi S, et al. (2007). Galectin-3 expression in colorectal cancer: relation to invasion and metastasis. Anticancer Res, 27(4B), 2289–2296.
Search in Google Scholar Back to article
70. Kim H, Lin H, Biliran H, Raz A. (1999). Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res, 59(16), 4148–4154.
Search in Google Scholar Back to article
71. Matarrese P, Tinari N, Semeraro M, Natoli C, Iacobelli S, Malorni W. (2000). Galectin-3 overexpression protects from cell damage and death by influencing mitochondrial homeostasis. FEBS Lett, 473(3), 311–315.10.1016/S0014-5793(00)01547-7
Search in Google Scholar Back to article
72. Takenaka Y, Fukumori T, Yoshii T, Oka N, Inohara H, Kim H-RC, et al. (2004). Nuclear export of phosphorylated galectin-3 regulates its antiapoptotic activity in response to chemotherapeutic drugs. Mol Cell Biol, 24(10), 4395–4406.10.1128/MCB.24.10.4395-4406.200440047515121858
Search in Google Scholar Back to article
73. Nangia-Makker, Wang Y, Raz T, Tait L, Balan V, Hogan V, et al. (2010). Cleavage of galectin-3 by matrix metallo proteases in duces angiogenesis in breast cancer. Int J Cancer, 127(11), 2530–2541.10.1002/ijc.25254333485720162566
Search in Google Scholar Back to article
74. Shimura T, Takenaka Y, Tsutsumi S, Hogan V, Kikuchi A, Raz A. (2004). Galectin-3, a novel binding partner of betacatenin. Cancer Res, 64(18), 6363-6367.10.1158/0008-5472.CAN-04-181615374939
Search in Google Scholar Back to article
75. Song S, Mazurek N, Liu C, Sun Y, Ding QQ, Liu K, et al. (2009). Galectin-3 mediates nuclear betacatenin accumulation and Wnt signaling in human colon cancer cells by regulation of glycogen synthase kinase-3beta activity. Cancer Res, 69(4), 1343-1349.10.1158/0008-5472.CAN-08-4153299040019190323
Search in Google Scholar Back to article
76. Harazono Y, Kho DH, Balan V, Nakajima K, Zhang T, Hogan V, et al. (2014). Galectin-3 leads to attenuation of apoptosis through Bax heterodimerization in human thyroid carcinoma cells. Oncotarget, 5(20), 9992-10001.10.18632/oncotarget.2486425945325393982
Search in Google Scholar Back to article
77. Cheng YL, Huang WC, Chen CL, Tsai CC, Wang CY, Chiu WH, et al. (2011). Increased galectin-3 facilitates leukemia cell survival from apoptotic stimuli. Biochem Biophys Res Commun, 412, 334-340.10.1016/j.bbrc.2011.07.09921821001
Search in Google Scholar Back to article
78. Cheong TC, Shin JY, Chun KH. (2010). Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents. Cancer Sci, 101, 94-102.10.1111/j.1349-7006.2009.01364.x19843071
Search in Google Scholar Back to article
79. Lee YK, Lin TH, Chang CF, Lo YL. (2013). Galectin-3 silencing inhibits epirubicin-induced ATP binding cassette transporters and activates the mitochondrial apoptosis pathway via β-catenin/GSK-3β modulation in colorectal carcinoma. PLoS One, 8(11), e82478.10.1371/journal.pone.0082478384114324303084
Search in Google Scholar Back to article
80. Califice S, Castronovo V, Van Den Brule F. (2004). Galectin-3 and cancer. Int J Oncol, 25, 983–92.
Search in Google Scholar Back to article
81. Friedl P, Alexander S. (2011). Cancer invasion and the microenvironment: plasticity and reciprocity. Cell, 147(5), 992–1009.10.1016/j.cell.2011.11.01622118458
Search in Google Scholar Back to article
82. Nangia-Makker P, Balan V, Raz A. (2008). Regulation of tumor progression by extracellular galectin-3. Cancer Microenviron, 1(1), 43–51.10.1007/s12307-008-0003-6265434719308684
Search in Google Scholar Back to article
83. Yu LG, Andrews N, Zhao Q, McKean D, Williams JF, Connor LJ, et al. (2007). Galectin-3 interaction with Thomsen-Friedenreich disaccharide on cancer associated MUC1 causes increased cancer cell endothelial adhesion. J Biol Chem, 282, 773–781.10.1074/jbc.M60686220017090543
Search in Google Scholar Back to article
84. Zhao Q, Guo X, Nash GB, Stone PC, Hilkens J, Rhodes JM, et al. (2009). Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. Cancer Res, 69, 6799–6806.10.1158/0008-5472.CAN-09-1096274161019690136
Search in Google Scholar Back to article
85. Zhao Q, Barclay M, Hilkens J, Guo X, Barrow H, Rhodes JM, et al. (2010). Interaction between circulating galectin-3 and cancer-associated MUC1 enhances tumor cell homotypic aggregation and prevents anoikis. Mol Cancer, 9:154.
Search in Google Scholar Back to article
86. Radosavljevic G, Jovanovic I, Majstorovic I, Mitrovic M, Lisnic V, Arsenijevic N, et al. (2011). Deletion of galectin-3 in the host attenuates metastasis of murine melanoma by modulating tumor adhesion and NK cell activity. Clin Exp Metastasis, 28(5), 451–462.10.1007/s10585-011-9383-y21442355
Search in Google Scholar Back to article
87. Dange MC, Srinivasan N, More SK, Bane SM, Upadhya A, Ingle AD, et al. (2014). Galectin-3 expressed on different lung compartments promotes organ specific metastasis by facilitating arrest, extravasation and organ colonization via high affinity ligands on melanoma cells. Clin Exp Metastasis, 31, 661-673.10.1007/s10585-014-9657-224952269
Search in Google Scholar Back to article
88. More SK, Srinivasan N, Budnar S, Bane SM, Upadhya A, Thorat RA, et al. (2015). N-glycans and metastasis in galectin-3 transgenic mice, Biochemical and Biophysical Research Communications, 460, 302-307.10.1016/j.bbrc.2015.03.03025791476
Search in Google Scholar Back to article
89. Markowska AI, Liu FT, Panjwani N. (2010). Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J Exp Med, 207, 1981–1993.10.1084/jem.20090121293117220713592
Search in Google Scholar Back to article
90. Lindau D, Gielen P, Kroesen M, Wesseling P, Adema GJ. (2013). The immunosuppressive tumour network: myeloid-derived suppressor cells, regulatory T cells and natural killer T cells. Immunology, 138, 105–115.10.1111/imm.12036357576323216602
Search in Google Scholar Back to article
91. Motz GT, Coukos G. (2013). Deciphering and reversing tumor immune suppression. Immunity, 39, 61–73.10.1016/j.immuni.2013.07.005378239223890064
Search in Google Scholar Back to article
92. Demotte N, Wieers G, VanDer Smissen P, Moser M, Schmidt C, Thielemans K, et al. (2010). A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res, 70, 7476–7488.10.1158/0008-5472.CAN-10-076120719885
Search in Google Scholar Back to article
93. Chen HY, Fermin A, Vardhana S, Weng IC, Lo KF, Chang EY, et al. (2009). Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse. Proc Natl Acad Sci USA, 106, 14496–14501.10.1073/pnas.0903497106273279519706535
Search in Google Scholar Back to article
94. Fukumori T, Takenaka Y, Yoshii T, Kim HR, Hogan V, Inohara H, et al. (2003). CD29 and CD7 mediate galectin-3-induced type II T-cell apoptosis. Cancer Res, 63, 8302–8311.
Search in Google Scholar Back to article
95. Kouo T, Huang L, Pucsek AB, Cao M, Solt S, Armstrong T, et al. (2015). Galectin-3 Shapes Antitumor Immune Responses by Suppressing CD8+ T Cells via LAG-3 and Inhibiting Expansion of Plasmacytoid Dendritic Cells. Cancer Immunol Res, 3(4), 412-423.10.1158/2326-6066.CIR-14-0150439050825691328
Search in Google Scholar Back to article
96. Tsuboi S, Sutoh M, Hatakeyama S, Hiraoka N, Habuchi T, Horikawa Y, et al. (2011). A novel strategy for evasion of NK cell immunity by tumours expressing core 2 O-glycans. EMBO J, 30, 3173–3185.10.1038/emboj.2011.215316018921712812
Search in Google Scholar Back to article
97. Wang JM, Cheng YQ, Shi L, Ying RS, Wu XY, Li GY, et al. (2013). KLRG1 negatively regulates natural killer cell functions through the Akt pathway in individuals with chronic hepatitis C virus infection. J Virol, 87(21), 11626-11636.10.1128/JVI.01515-13380733723966413
Search in Google Scholar Back to article
98. Jiang HR, Al Rasebi Z, Mensah-Brown E, Shahin A, Xu D, Goodyear CS, et al. (2009). Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis. J Immunol, 182, 1167–1173.10.4049/jimmunol.182.2.116719124760
Search in Google Scholar Back to article
99. Fermino ML, Dias FC, Lopes CD, Souza MA, Cruz ÂK, Liu FT, et al. (2013). Galectin-3 negatively regulates the frequency and function of CD4(+) CD25(+) Foxp3(+) regulatory T cells and influences the course of Leishmania major infection. Eur J Immunol, 43(7), 1806-1817.10.1002/eji.20134338123592449
Search in Google Scholar Back to article
100. Orentas RJ, Kohler ME, Johnson BD. (2006). Suppression of anti-cancer immunity by regulatory T cells: back to the future. Semin Cancer Biol, 16, 137–149.10.1016/j.semcancer.2005.11.007
Search in Google Scholar Back to article
101. Ghiringhelli F, Menard C, Terme M, Flament C, Taieb J, Chaput N, et al. (2005). CD4+CD25+ regulatory T cells inhibit natural killer cell functions in a transforming growth factor-beta-dependent manner. J Exp Med, 202, 1075–1085.10.1084/jem.20051511
Search in Google Scholar Back to article
102. Murugaiyan G, Saha B. (2009). Protumor vs antitumor functions of IL-17. J Immunol, 183(7), 4169-4175.10.4049/jimmunol.0901017
Search in Google Scholar Back to article
103. Ikeda H, Old LJ, Schreiber RD. (2002). The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev, 13, 95–109.10.1016/S1359-6101(01)00038-7
Search in Google Scholar Back to article
104. Xu Z, Hurchla MA, Deng H, Uluckan O, Bu F, Berdy A, et al. (2009). Interferon-gamma targets cancer cells and osteoclasts to prevent tumor-associated bone loss and bone metastases. J Biol Chem, 284, 4658–4666.10.1074/jbc.M804812200264097319059914
Search in Google Scholar Back to article
105. Mitra-Kaushik S, Harding J, Hess J, Schreiber R, Ratner L. (2004). Enhanced tumorigenesis in HTLV-1 tax-transgenic mice deficient in interferon-gamma. Blood, 104, 3305–3311.10.1182/blood-2004-01-026615292059
Search in Google Scholar Back to article
106. Kakuta S, Tagawa Y, Shibata S, Nanno M, Iwakura Y. (2002). Inhibition of B16 melanoma experimental metastasis by interferon-gamma through direct inhibition of cell proliferation and activation of antitumour host mechanisms. Immunology, 105, 92–100.10.1046/j.0019-2805.2001.01342.x178264011849319
Search in Google Scholar Back to article
107. Wu SY, Yu JS, Liu FT, Miaw SC, Wu-Hsieh BA. (2013). Galectin-3 negatively regulates dendritic cell production of IL-23/IL-17-axis cytokines in infection by Histoplasma capsulatum. J Immunol, 190, 3427–3437.10.4049/jimmunol.120212223455499
Search in Google Scholar Back to article
108. Fermin Lee A, Chen HY, Wan L, Wu SY, Yu JS, Huang AC, et al. (2013). Galectin-3 modulates th17 responses by regulating dendritic cell cytokines. Am J Pathol, 183, 1209–1222.10.1016/j.ajpath.2013.06.017379168723916470
Search in Google Scholar Back to article
109. Newlaczyl AU, Yu L-G. (2011). Galectin-3 – A jack-of-all-trades in cancer. Cancer Letters, 313, 123–128.10.1016/j.canlet.2011.09.00321974805
Search in Google Scholar Back to article
110. Song L, Tang J-W, Owusu L, Sun M-Z, Wu J, Zhang J. (2014). Galectin-3 in cancer. Clinica Chimica Acta, 431, 185–191.10.1016/j.cca.2014.01.01924530298
Search in Google Scholar Back to article
111. Gabius HJ, Kayser K. (2014). Introduction to glycopathology: the concept, the tools and the perspectives. Diagn Pathol, 9:4.
Search in Google Scholar Back to article

Articles in this issue

DOI: https://doi.org/10.1515/sjecr-2016-0011 | Journal eISSN: 2956-2090 | Journal ISSN: 2956-0454

Journal RSS Feed

Language: English

Page range: 187 - 198

Submitted on: Dec 23, 2015

Accepted on: Jan 10, 2016

Published on: Sep 24, 2016

Published by: University of Kragujevac, Faculty of Medical Sciences

In partnership with: Paradigm Publishing Services

Publication frequency: 4 issues per year

Keywords:

tumour,

Related subjects:

Clinical medicine, other

© 2016 Gordana D. Radosavljevic, Jelena Pantic, Ivan Jovanovic, Miodrag L. Lukic, Nebojsa Arsenijevic, published by University of Kragujevac, Faculty of Medical Sciences
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Volume 17 (2016): Issue 3 (September 2016)